Introduction
Cross-talk between cell-surface receptors expands the continuum of signaling pathways activated by a single ligand. The epidermal growth factor receptor (EGFR) serves as a convergence point for receptor transactivation events initiated by G-protein coupled receptors (GPCRs) (Daub et al., 1996; Prenzel et al., 1999) , cytokine receptors (Yamauchi et al., 1997) and integrins (Miyamoto et al., 1996; Moro et al., 1998) . Transactivation of the EGFR by GPCR ligands including endothelin-1, thrombin and lysophosphatidic acid, is necessary for activation of the Ras-ERK pathway, induction of c-fos and DNA synthesis (Daub et al., 1996) . EGFR transactivation downstream of the integrins, a v b 3 and a 5 b 1 , supports adhesion-dependent cell survival (Moro et al., 1998) .
EGFR transactivation may be ligand-dependent or -independent. Ligand-dependent transactivation involves release of membrane-anchored EGFR ligands, typically by matrix metalloproteases (Prenzel et al., 1999; Yan et al., 2002) . Ligand-independent mechanisms involve non-receptor tyrosine kinases such as Jak-2 and c-Src, which target the EGFR (Luttrell et al., 1997; Yamauchi et al., 1997) . The function of the EGFR, as a downstream mediator of signaling events initiated by other receptors, may not always require EGFR tyrosine kinase activity. For example, in growth hormone-treated cells, Tyr-1068 in the EGFR is phosphorylated by Jak-2 and serves as a docking site for Grb2 (Yamauchi et al., 1997) .
The EGFR is directly activated by EGF, transforming growth factor-a, heparin-binding EGF-like growth factor and amphiregulin. These growth factors dimerize the EGFR or mediate heterodimerization with the related receptors, HER2-neu/ErbB2 and HER4/ErbB4 (Singh and Harris, 2005) . Within dimers, the EGFR expresses intrinsic tyrosine kinase activity and autophosphorylates multiple tyrosine residues that serve as docking sites for adaptor proteins involved in the activation of ERK, phosphatidylinositol-3 kinase, protein kinase C and phospholipase C-g.
The function of receptors outside the EGFR family as mediators of the response to EGF has received little attention. Urokinase-type plasminogen activator (uPA) is a serine protease that binds to the receptor, uPAR (Blasi and Carmeliet, 2002) . Like the EGFR, uPAR is frequently overexpressed in breast cancer and associated with rapidly progressive disease (Bolla et al., 1990; Duffy et al., 1999) . uPA-binding to uPAR activates multiple cell signaling proteins including FAK, c-Src and ERK (Nguyen et al., 1998 ; Aguirre Ghiso et al., 1999; Monaghan-Benson and Mckeown-Longo, 2006) . As uPAR is glycosyl phosphatidylinositol (GPI)-anchored, its function in cell signaling requires co-receptors that may include integrins, the EGFR, FPR-like receptor-1/lipoxin A4 receptor (FPRL1), platelet-derived growth factor b-receptor and gp130 (Wei et al., 1996; Koshelnick et al., 1997; Liu et al., 2002; Resnati et al., 2002; Jo et al., 2003; Kiyan et al., 2005) . uPAR co-receptors may determine the response to uPA, such as whether cell proliferation is observed (Jo et al., 2005) . The possibility that uPAR is involved in cell-signaling in response to growth factors other than uPA has not been considered.
In this paper, we report that uPAR is required for EGF to induce proliferation of murine embryonic fibroblasts (MEFs) and MDA-MB 231 breast cancer cells. uPAR deficiency does not alter EGFR expression or the kinetics of ERK activation by EGF; however, uPAR is necessary for phosphorylation of Tyr-845 in the EGFR and for activation of STAT5b, which occur downstream of c-Src in EGF-treated cells and are essential for EGF-induced cell growth Tice et al., 1999; Kloth et al., 2003) . c-Src overexpression rescues EGF mitogenic activity in the absence of uPAR. Our results support a model, in which uPAR primes the cell to proliferate in response to EGF by facilitating activation of STAT5b.
Results

EGF-induced MEF growth requires uPAR
To examine the role of uPAR in EGF-promoted cell growth, we analysed uPARÀ/À A1 and A2 MEFs and uPAR þ / þ C1 and C2 MEFs. These previously described cell lines were prepared from littermate embryos by breeding uPAR þ /À mice and immortalized with SV-40 large T antigen (Ma et al., 2002) . Serumstarved cells were treated for 48 h with EGF or with vehicle. Cell growth was determined by the MTT assay, which reports the total number of viable cells. In the absence of EGF, uPAR-expressing and -deficient MEFs demonstrated similar levels of cell growth (10-30% increase in cell number); however, EGF significantly increased cell growth (Po0.01) only in the uPAR þ / þ cells ( Figure 1a) . These results suggested that in MEFs, uPAR may be necessary for EGF mitogenic activity.
The lack of response to EGF in uPARÀ/À MEFs did not reflect regulation of EGFR expression. All four MEF cell lines demonstrated equivalent levels of EGFR mRNA, as determined by reverse transcriptase PCR ( Figure 1b ) and equivalent levels of EGFR protein, as determined by immunoblot analysis (Figure 1c ). uPA mRNA also was expressed in all four MEF cell lines, as anticipated. To confirm that uPA protein is produced and available to bind uPAR in C1 and C2 cells, we cultured the four MEF cell lines in serum-free medium for 18 h. After washing, cell-associated uPA was detected by a coupled enzyme assay with purified plasminogen and the plasmin-specific substrate, H-DVal-L-Leu-L-Lys-p-nitroanilide (VLK-pNA). This assay detects uPA, which is rapidly activated by plasmin at the cell surface (Weaver et al., 1997) . As shown in Figure 1d , cell-associated uPA was detected in the uPAR-positive MEFs. Endogenously produced uPA may establish autocrine uPAR-dependent cell signaling (Ma et al., 2002) .
Rescuing the response to EGF in uPARÀ/À MEFs We transfected uPARÀ/À A1 cells to express human uPAR, which does not bind murine uPA (Estreicher et al., 1989) precluding autocrine cell-signaling. Human uPAR expression was confirmed by immunoblot analysis ( Figure 2a ) and by the response of these cells to human uPA in the MTT cell growth assay; however, human uPAR-expressing A1 cells failed to grow in response to EGF (Figure 2b ). We further examined the effects of human uPAR expression in MEFs by measuring BrdU incorporation, an index of DNA synthesis in S phase. C1 cells, A1 cells, and A1 cells that express human uPAR were treated with EGF or vehicle and BrdU for 4 h. In the absence of EGF (control), BrdU incorporation was similar in all three cell types (4573% in C1 cells, 4173% in A1 cells and 3873% in human uPARexpressing A1 cells). EGF increased DNA synthesis in the uPAR þ / þ C1 cells but not in the uPARÀ/À A1 cells, even when these cells expressed human uPAR (Figure 2c ). Thus, human uPAR does not rescue the response to EGF in uPAR-deficient MEFs. Furthermore, the MTT assay and BrdU incorporation report the response to EGF in uPAR-expressing and -deficient MEFs equivalently.
Next, we cloned murine uPAR by 5 0 rapid amplification of cDNA ends (RACE). An expression construct containing the full-length clone was expressed in uPARÀ/À A1 cells. Murine uPAR expression was confirmed by a coupled enzyme assay in which the cells were loaded with exogenous murine uPA, washed, and incubated with purified plasminogen and VLK-pNA. As shown in Figure 3a , murine uPAR expression in the uPARÀ/À MEFs significantly increased the capacity of these cells to support plasminogen activation. Plasminogen activation was unchanged in cells that were transfected with empty vector (pCDNA). . Cell-surface uPAR was detected by a coupled enzyme assay using purified uPA, plasminogen and VLK-pNA. (b) uPARÀ/À cells were transfected to express GFP and murine uPAR or GFP alone. The cells were then treated with EGF (10 ng/ml) or vehicle ('con') and BrdU for 4 h. Cell proliferation was determined as the fraction of GFPexpressing cells also positive for BrdU and expressed as the 'foldincrease in BrdU incorporation' relative to cells transfected with empty vector and treated with vehicle (mean7s.e.m., n ¼ 4).
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To determine whether murine uPAR rescues the response to EGF in uPARÀ/À MEFs, BrdU incorporation was studied. Cells were co-transfected with pEGFP so that BrdU incorporation could be determined selectively in the transfected population. In cells transfected with empty vector (pCDNA), EGF failed to increase BrdU incorporation, whereas in murine uPAR-expressing cells, a significant increase (Po0.01) in BrdU-positive cells was observed (Figure 3b ). The ability of murine uPAR but not human uPAR to rescue the mitogenic activity of EGF suggests that binding of endogenously produced uPA may be essential.
Regulation of EGF-induced Tyr-845 phosphorylation and STAT5b activation
The function of EGF as a mitogen requires activation of ERK and phosphorylation of Tyr-845 in the EGFR, which is a known c-Src substrate involved in the STAT5b activation Tice et al., 1999; Kloth et al., 2003) . To determine whether uPAR regulates EGF-induced cell-signaling, first we examined EGFR phosphorylation. uPAR þ / þ and uPARÀ/À MEFs were treated with EGF for 10 min. EGFR phosphorylation was equivalent in all four cell lines as determined using a pan-phospho-EGFR antibody (Figure 4a ). By contrast, significant Tyr-845 phosphorylation occurred only in the uPAR þ / þ C1 and C2 MEFs. The uPARÀ/À A1 and A2 MEFs cells demonstrated a slight increase in Tyr-845 phosphorylation in response to EGF; however, the band was substantially reduced in intensity compared with that observed in EGF-treated C1 and C2 cells.
We probed the identical cell extracts to detect phosphorylated ERK, total ERK and total c-Src. No differences were observed before or after treatment with EGF. As the extent of Tyr-845 phosphorylation in response to EGF was different in the uPAR þ / þ and uPARÀ/À MEFs, we hypothesized that STAT5b activation also would be different. To test this hypothesis, STAT5b phosphorylation was examined. EGF increased STAT5b tyrosine phosphorylation only in the uPAR þ / þ MEFs (Figure 4b ).
To further probe for differences in cell signaling in response to EGF in uPAR þ / þ and uPARÀ/À MEFs, we conducted kinetic analyses of EGFR phosphoryation and ERK activation. In uPAR þ / þ C1 cells and in uPARÀ/À A1 cells, phosphorylation of the EGFR and ERK were transient; however, uPAR expression did not significantly alter the kinetics of either response ( Figure 5 ).
Autocrine uPAR-dependent cell signaling regulates EGF mitogenic activity The ability of murine uPAR but not human uPAR to rescue the mitogenic activity of EGF in uPARÀ/À MEFs suggested that binding of endogenously produced uPA to uPAR may be essential. uPA-binding to uPAR activates c-Src and other Src family kinases (Resnati et al., 2002; Monaghan-Benson and McKeown-Longo, 2006) , which may be responsible for phosphorylation of Tyr-845 in the EGFR. As a first approach to test whether autocrine uPAR-dependent cell signaling is necessary for the mitogenic activity of EGF, we determined the activity of a synthetic peptide, a325, that disrupts uPAR-integrin interactions known to be necessary for uPAR-dependent cell-signaling (Wei et al., 2001) . As shown in Figure 6 , a325 inhibited BrdU incorporation in response to EGF by >60% (Po0.05). A scrambled version of a325 had no effect.
Next, we tested whether c-Src overexpression in uPARÀ/À MEFs rescues the ability of these cells to proliferate in response to EGF. We confirmed that c-Src was expressed in transfected cells by immunoblot analysis (Figure 7a ). c-Src overexpression did not induce an increase in cell proliferation in the absence of additional stimulants; however, in response to EGF, c-Src-overexpressing MEFs demonstrated significantly uPAR is essential for EGF-induced breast cancer cell growth To test whether uPAR regulates the mitogenic activity of EGF in a second model system, we studied MDA-MB 231 breast cancer cells. First, a gene-silencing approach was applied. uPAR-specific siRNA silenced uPAR without affecting EGFR expression, as determined by immunoblot analysis (Figure 8a ). Pooled nontargeting control siRNA had no effect on either receptor. MDA-MB 231 cells, in which uPAR was silenced, control cells transfected with non-targeting siRNA, and untransfected cells were treated with EGF for 48 h. MTT assays were then performed. Untransfected cells demonstrated rapid growth in the absence of EGF (126723% increase in cell number) and significantly increased growth (Po0.05) in the presence of EGF (Figure 8b) . Equivalent results were obtained using cells transfected with non-targeting siRNA. When uPAR was silenced, the basal level of MDA-MB 231 cell growth was decreased. This was anticipated because autocrine uPAR cell-signaling supports MDA-MB 231 cell proliferation and survival (Ma et al., 2001) . uPAR gene A synthetic peptide that blocks association of uPAR with integrins inhibits EGF-induced MEF proliferation. uPAR þ / þ MEFs were pre-treated with a325 or scrambled (sc) a325 (100 mM) for 30 min, and then with EGF (10 ng/ml) or vehicle ('con') and BrdU for 4 h. Cell proliferation was determined by BrdU incorporation. The asterisk indicates that the values are significantly different at the Po 0.05 level (mean7s.e.m., n ¼ 3). uPAR regulates the mitogenic activity of EGF M Jo et al silencing also completely blocked cell growth in response to EGF. Similar results were obtained when we silenced uPAR in a second breast cancer cell line, MDA-MB 468 (results not shown).
Next, we studied the effects of the synthetic peptide, a325, on MDA-MB 231 cell proliferation by measuring BrdU incorporation. When MDA-MB 231 cells were maintained in serum-free medium for 18 h, 3174% of the cells were BrdU-positive. The percentage of BrdUpositive cells was significantly increased by EGF (Figure 8c ). a325 decreased BrdU incorporation by about 20% in the absence of EGF, matching the decrease observed with scrambled a325; however, the scrambled peptide failed to affect cell proliferation in response to EGF whereas a325 entirely blocked EGFinduced BrdU incorporation. These studies and our gene silencing results support the hypothesis that uPARdependent cell-signaling is necessary for EGF-induced MDA-MB 231 cell proliferation.
To further test this hypothesis, we assessed the activity of antibodies previously shown to block autocrine uPAR-dependent cell-signaling in MDA-MB 231 cells (Ma et al., 2001) . MDA-MB 231 cells were treated with uPA-specific antibody 3471 or uPARspecific antibody 399R for 18 h, with or without EGF. Control cultures were treated with non-specific IgG. EGF significantly increased BrdU incorporation in the presence of non-specific IgG; however, both specific antibodies blocked the response (Figure 8d) . As a control, we examined BrdU incorporation in response to 10% FBS. Antibody 399R had no effect on the mitogenic activity of the FBS.
MDA-MB 231 cells express low levels of c-Src compared with other breast cancer cell lines, such as SK-BR3 (Biscardi et al., 1998 ). Therefore, we tested whether c-Src overexpression in MDA-MB 231 cells restores the response to EGF in the presence of antibody 399R. c-Src was overexpressed together with pEGFP to selectively study BrdU incorporation in the transfected population. c-Src overexpression was confirmed by immunoblot analysis (results not shown). Figure 9a shows that c-Src overexpression rescued EGF mitogenic activity in the presence of antibody 399R (Po0.01). This result suggests that the mechanism by which uPAR supports the mitogenic activity of EGF may be Figure 8 uPAR is required for EGF-induced MDA-MB 231 cell growth and proliferation. (a) Extracts from cells transfected with uPAR-specific siRNA or non-targeting control siRNA were prepared at the indicated times and subjected to immunoblot analysis to detect EGFR, uPAR and ERK, as a loading control. (b) MDA-MB 231 cells that were transfected with uPAR-specific siRNA or non-targeting siRNA were treated with EGF (10 ng/ml) or vehicle ('con') for 48 h in 1% FBS-containing medium. The MTT assay was then performed. The increase in viable cells relative to the 0 h point is presented (mean7s.e.m.). (c) MDA-MB 231 cells were pre-treated with a325 or sca325 (100 mM) for 30 min, and then incubated with the same peptide and EGF (100 ng/ml) or vehicle ('con') and BrdU (100 mM) for 18 h. Cell proliferation was determined by BrdU incorporation. As the basal level of BrdU incorporation was 31%, the theoretical maximum increase in BrdU incorporation was 3.3-fold. (d) MDA-MB 231 cells were pretreated with non-specific mouse IgG (M IgG), rabbit IgG (R IgG), uPA-specific antibody 3471 or uPAR-specific antibody 399R (25 mg/ml) for 30 min. The cells were then treated with BrdU and EGF (100 ng/ml), 10% fetal bovine serum (FBS) or vehicle ('con') for 18 h, as indicated. Cell proliferation was determined by BrdU incorporation (mean7s.e.m., n ¼ 3).
uPAR regulates the mitogenic activity of EGF M Jo et al equivalent in MEFs and MDA-MB 231 breast cancer cells. Next, we assessed STAT5b phosphorylation in response to EGF in the presence and absence of antibody 399R. Although antibody 399R did not entirely block STAT5b phosphorylation, a substantial decrease was observed (Figure 9b) . These results support a model in which uPAR-dependent cell-signaling regulates the mitogenic activity of EGF by controlling the extent of STAT5b activation.
Discussion
The EGFR and uPAR activate similar downstream signaling pathways and regulate common cell physiologic processes including growth, apoptosis and cell migration (Blasi and Carmeliet, 2002; Singh and Harris, 2005) . Thus, it is not entirely surprising that the EGFR may be transactivated when uPA binds to uPAR (Liu et al., 2002; Jo et al., 2003) . Other receptors also have been implicated in the cell signaling events triggered by uPA-binding to uPAR including FPRL1, integrins, platelet-derived growth factor b-receptor and gp130 (Wei et al., 1996; Koshelnick et al., 1997; Resnati et al., 2002; Kiyan et al., 2005) . Whether these receptors are interchangeable or assemble into multiprotein complexes with uPAR is a topic of current investigation. In CHO cells, the EGFR is not required for ERK activation by uPA; however, uPA-induced STAT5b activation requires the EGFR (Jo et al., 2003 (Jo et al., , 2005 . By contrast, a pertussis toxin-sensitive GPCR is required for uPA-initiated ERK activation, irrespective of whether the EGFR is expressed.
The requirement of co-receptors in uPAR-initiated cell-signaling seems reasonable given that uPAR is GPIanchored. However, uPAR has received little attention in cell-signaling pathways activated by ligands other than uPA. In this study, we demonstrate that uPAR may regulate the cellular response to EGF. Our evidence indicates that the responsible mechanism involves the ability of uPAR to control phosphorylation of Tyr-845 in the EGFR in response to EGF, and the downstream event, activation of STAT5b. EGF-induced activation of STAT5b, accompanied by activation of Ras and ERK, promotes cell growth Tice et al., 1999; Kloth et al., 2003) . Tyr-845 phosphorylation also promotes binding of cytochrome-c oxidase subunit II to the EGFR, which increases cell survival and tumorigenesis (Boerner et al., 2004) . The ability of uPAR to regulate Tyr-845 phosphorylation and STAT5b activation in response to EGF suggests that uPAR may control the cellular response to other EGFR ligands as well.
Regulation of Tyr-845 phosphorylation in response to EGF may be explained if uPAR controls the activity of c-Src, activates an alternative cell-signaling pathway that results in Tyr-845 phosphorylation, and/or alters the availability of Tyr-845 in EGF-treated cells. The latter mechanism implies an effect of uPAR on the conformational state of the EGFR after EGF-induced dimerization. We favor a model in which uPARdependent autocrine cell signaling increases the activity of enzymes that phosphorylate Tyr-845. uPAR is known to control the activity of c-Src and other Src family members (Resnati et al., 2002; Monaghan-Benson and McKeown-Longo, 2006) . The ability of murine uPAR but not human uPAR to support the mitogenic activity of EGF is consistent with a model in which autocrine uPAR cell-signaling is essential. The inhibitory activity of a325 is also consistent with the model. In many cell types, including MEFs, uPAR-dependent cell signaling is the dominant autocrine pathway established in serumfree medium because uPAR is highly sensitive to low concentrations of uPA (Ma et al., 2001 (Ma et al., , 2002 . We propose that uPAR-dependent autocrine signaling primes the cell to respond to EGF.
The ability of c-Src overexpression to rescue the mitogenic activity of EGF in uPARÀ/À MEFs and in antibody 399R-treated MDA-MB 231 cells further supports our model in which autocrine uPAR-dependent Figure 9 uPAR regulates the signaling response to EGF in MDA-MB 231 cells. (a) MDA-MB 231 cells were transfected with constructs encoding GFP and c-Src or empty vector, subjected to a mild acid wash, pre-incubated with non-specific IgG (R IgG) or uPAR-specific antibody 399R (25 mg/ml), and then treated with EGF (100 ng/ml) or vehicle ('con') and BrdU. Cell proliferation was determined as the fraction of GFP-expressing cells that were also positive for BrdU. (b) MDA-MB 231 cells were treated with non-specific IgG (R IgG) or antibody 399R for 18 h, and then treated with EGF (100 ng/ml) or vehicle for 15 min. Nuclear extracts were immunoprecipitated using STAT5b-specific antibody. The precipitates were subjected to immunoblot assay to detect phosphorylated STAT5b. The original nuclear extracts also were subjected to immunoblot analysis to detect lamin.
uPAR regulates the mitogenic activity of EGF M Jo et al cell signaling primes the cell to respond to EGF. However, these results also lend insight into specific conditions that may be required for our results to be relevant in vivo. The basal level of c-Src in the cell is clearly critical in determining whether uPAR-dependent cell signaling is necessary to support the mitogenic activity of EGF. Although the uPAR gene knockout mouse demonstrates abnormalities in inflammatory cell adhesion and migration, these mice are devoid of major developmental abnormalities (Blasi and Carmeliet, 2002) . By contrast, disruption of the EGFR gene is embryonic lethal or lethal shortly after birth, due to major abnormalities in multiple organs involving primarily epithelial cells (Miettinen et al., 1995; Threadgill et al., 1995) . Thus, uPAR deficiency does not appear to compromise EGFR function in development, probably because of other redundant pathways that are capable of activating c-Src in well-perfused tissues. The redundant pathways may involve any of a number of blood-borne growth factors (Abram and Courtneidge, 2000) . We hypothesize that uPAR-dependent cellsignaling may be critical for the mitogenic activity of EGF in poorly perfused, hypoxic tissues, which frequently exist within growing cancers. Furthermore, the spectrum of EGF receptors expressed by the cell may influence whether uPAR plays a significant role in controlling EGF mitogenic activity since HER2-neu/ ErbB2 binds and activates c-Src as well (Kim et al., 2005) .
Overexpression of EGFR family members and c-Src may be particularly potent in promoting breast cancer growth and progression (Biscardi et al., 2000) . Our results suggest an alternative combination of events, overexpression of the EGFR and uPAR that may negate the need for c-Src overexpression and induce equivalent changes in cancer cell behavior. The previously identified function of the EGFR in uPA-initiated cell signaling (Liu et al., 2002; Jo et al., 2003; Angelucci et al., 2006) and the pathway described here support a model in which uPAR, the EGFR and c-Src are intimately linked in determining breast cancer progression and prognosis.
In a previous study, uPA and uPAR were shown to be necessary for EGF-induced prostate carcinoma cell migration (Mamoune et al., 2004) ; however, the mechanism involved EGF-induced upregulation of expression of uPA and uPAR, as opposed to a direct effect of uPAR on EGF-initiated cell signaling. In control experiments, we proved that EGFR expression is not altered by uPAR deficiency in MEFs and MDA-MB 231 breast cancer cells. EGFR tyrosine phosphorylation in response to EGF was equivalent in uPAR þ / þ and uPARÀ/À MEFs, when assessed using a panphospho-EGFR-specific antibody. Furthermore, our c-Src overexpression experiments prove that under specific conditions, the requirement for uPAR in supporting EGF mitogenic activity is eliminated. Mazzieri et al. (2006) reported that uPARÀ/À MEFs demonstrate more rapid proliferation and oncogenic transformation, compared with uPAR-positive cells; however, their MEFs were not transformed with SV40 large T antigen. As our MEFs were transformed, the tumor suppressor gene p53 is inactivated (O'Reilly, 1986) , as may be observed in human cancers and cancer cell lines.
Overall, our results support a model in which EGFR ligation is followed by c-Src-dependent Tyr-845 phosphorylation and activation of STAT5b Tice et al., 1999; Kloth et al., 2003) . The extent to which this pathway is operational may depend on uPAR, especially in cells without high levels of c-Src. Our results confirm that activation of STAT5b is necessary for the mitogenic activity of EGF. Thus, uPAR-dependent cell signaling may prime cells to proliferate in response to EGF. Furthermore, malignant epithelial cells that express uPAR may show enhanced proliferation not only in response to uPA but also EGF.
Materials and methods
Reagents and antibodies
]plasminogen was purified from human plasma (Deutsch and Mertz, 1970) . High molecular-weight human uPA was provided by Dr Jack Henkin and inactivated with diisopropyl fluorophosphate to form DIP-uPA (Nguyen et al., 1998) . Murine uPA was from Molecular Innovations (Southfield, MI, USA). Human EGF was from R&D Systems (Minneapolis, MN, USA). The synthetic peptide, a325, and the scrambled version were provided by Dr Hal Chapman (University of California, San Francisco, CA, USA). Expression constructs encoding human uPAR, c-Src and kd-Src are previously described (Nguyen et al., 2000) . VLK-pNA, was from Bachem (King of Prussia, PA, USA). uPA-specific antibody 3471, uPAR-specific antibody 399R and uPAR-specific antibody 3932 were from American Diagnostica (Greenwich, CT, USA). Antibody that detects phosphorylated ERK was from Cell Signaling Technologies. Antibodies specific for total ERK, EGFR, phosphorylated-EGFR, lamin and phosphorylated STAT5b were from Upstate Biotechnologies (Lake Placid, NY, USA). Antibody specific for phosphorylated Tyr-845 was from Biosource (Camarillo, CA, USA). Phosphotyrosinespecific antibody PY20 was from B&D Biosciences (Franklin Lakes, NJ, USA). STAT5b-specific antibody was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). BrdU-specific antibody conjugated to Alexa Fluor 594 was from Invitrogen (Carlsbad, CA, USA).
Cloning of murine uPAR
Full-length murine uPAR cDNA was cloned by RACE, using MEF RNA, and inserted into pCDNA3.1 (see Supplementary Information).
Cell culture MEFs were cultured in DMEM supplemented with 10% FBS, penicillin (100 U/ml) and streptomycin (100 mg/ml). MDA-MB 231 cells were cultured in Leibowitz-15 medium with 10% FBS, penicillin and streptomycin. Experiments were performed no sooner than 18 h after passaging cultures. A1 cells were transfected to express human uPAR, using a full-length expression construct in pCDNA. Cultures were selected with hygromycin (0.5 mg/ml) and single-cell cloned. A1 cells also were transfected to express murine uPAR using our newly generated construct. The Nucleofactor (Amaxa) was used to electroporate the MEFs, yielding a transfection efficiency of 8874%. We confirmed murine uPAR expression by coupled uPAR regulates the mitogenic activity of EGF M Jo et al enzyme assay, as described by Weaver et al. (1997) .
[ Glu 1 ]plasminogen (1 mM), VLK-pNA (0.5 mM) and murine uPA (10 nM) were incubated with each culture for 2 h. Hydrolysis of VLK-pNA was detected by measuring the absorbance at 406 nm. To detect endogenously produced uPA, we applied a variation of this assay in which cells were incubated in serum-free medium for 18 h to allow capture of the uPA. Murine uPA was omitted from the final substrate mixture.
uPAR gene silencing Human uPAR-specific siRNA and pooled non-targeting siRNA (0.1 mM) were introduced into MDA-MB 231 and MDA-MB 468 cells using Oligofectamine (see Supplementary Information).
Immunoprecipitation and immunoblot analysis
Immunoprecipitation and immunoblot analysis were performed as previously described (Jo et al., 2005 ) (see Supplementary Information).
Cell growth and proliferation MTT assays and BrdU incorporation studies were performed as previously described (Jo et al., 2005 ) (see Supplementary  Information) .
